Alogliptin improves survival and health of mice on a high-fat diet

• Type of Material: Article
• Authors: Biao Zhu, Chinese Peoples Liberation Army General Hospital; Yixiang Li, Emory University; Lingwei Xiang, Allconnect Inc; Jiajia Zhang, Chinese Peoples Liberation Army General Hospital; Li Wang, Emory University; Bei Guo, Chinese Peoples Liberation Army General Hospital; Minglu Liang, Huazhong University of Science & Technology; Long Chen, Huazhong University of Science & Technology; Lin Xiang, Chinese Peoples Liberation Army General Hospital; Jing Dong, Chinese Peoples Liberation Army General Hospital; Min Liu, Chinese Peoples Liberation Army General Hospital; Wen Mei, Chinese Peoples Liberation Army General Hospital; Huan Li, Chinese Peoples Liberation Army General Hospital; Guangda Xiang, Chinese Peoples Liberation Army General Hospital
• Language: English
• Date: 2019-04-01
• Publisher: Wiley Open Access
• Publication Version: Final Published Version
• Copyright Statement: © 2019 The Authors.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1111/acel.12883
• Title of Journal or Parent Work: Aging Cell
• ISSN: 1474-9718
• Volume: 18
• Issue: 2
• Start Page: e12883
• End Page: e12883
• Grant/Funding Information: This work was supported by grants from National Natural Science Foundation of China (NSFC81370896, NSFC81570730), National Key Research and Development Program of China (2016YFC1305601), and Research Project of Hubei Health and Planning Commission (WJ2017H0031).
• Keywords: Cell Biology; Life Sciences & Biomedicine; SITAGLIPTIN; BETA-CELL FUNCTION; AUTOPHAGY; INSULIN-RESISTANCE; LEFT-VENTRICULAR DYSFUNCTION; LIFE-SPAN EXTENSION; Geriatrics & Gerontology; DPP-4 inhibitor; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; longevity; GLP-1; LIPID-ACCUMULATION; LIRAGLUTIDE; high-fat diet; Science & Technology; healthspan; GLUCAGON-LIKE PEPTIDE-1
• Research Categories: Biology, Cell; Health Sciences, General

Abstract

Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. Alogliptin is a commonly prescribed drug treating patients with type 2 diabetes. Here, we show that long-term intervention with alogliptin (0.03% w/w in diet) improves survival and health of mice on a high-fat diet. Alogliptin intervention takes beneficial effects associated with longevity, including increased insulin sensitivity, attenuated functionality decline, decreased organ pathology, preserved mitochondrial function, and reduced oxidative stress. Autophagy activation is proposed as an underlying mechanism of these beneficial effects. We conclude that alogliptin intervention could be considered as a potential strategy for extending lifespan and healthspan in obesity and overweight.